Article Text

Download PDFPDF
Multimorbidity pattern and risk of dementia in later life: an 11-year follow-up study using a large community cohort and linked electronic health records
  1. Mizanur Khondoker1,
  2. Alexander Macgregor1,
  3. Max O Bachmann1,
  4. Michael Hornberger1,
  5. Chris Fox1,2,
  6. Lee Shepstone1
  1. 1 Norwich Medical School, University of East Anglia, Norwich, UK
  2. 2 College of Medicine and Health, University of Exeter, Exeter, UK
  1. Correspondence to Dr Mizanur Khondoker, Norwich Medical School, University of East Anglia, Norwich, UK; m.khondoker{at}uea.ac.uk

Abstract

Background Several long-term chronic illnesses are known to be associated with an increased risk of dementia independently, but little is known how combinations or clusters of potentially interacting chronic conditions may influence the risk of developing dementia.

Methods 447 888 dementia-free participants of the UK Biobank cohort at baseline (2006–2010) were followed-up until 31 May 2020 with a median follow-up duration of 11.3 years to identify incident cases of dementia. Latent class analysis (LCA) was used to identify multimorbidity patterns at baseline and covariate adjusted Cox regression was used to investigate their predictive effects on the risk of developing dementia. Potential effect moderations by C reactive protein (CRP) and Apolipoprotein E (APOE) genotype were assessed via statistical interaction.

Results LCA identified four multimorbidity clusters representing Mental health, Cardiometabolic, Inflammatory/autoimmune and Cancer-related pathophysiology, respectively. Estimated HRs suggest that multimorbidity clusters dominated by Mental health (HR=2.12, p<0.001, 95% CI 1.88 to 2.39) and Cardiometabolic conditions (2.02, p<0.001, 1.87 to 2.19) have the highest risk of developing dementia. Risk level for the Inflammatory/autoimmune cluster was intermediate (1.56, p<0.001, 1.37 to 1.78) and that for the Cancer cluster was least pronounced (1.36, p<0.001, 1.17 to 1.57). Contrary to expectation, neither CRP nor APOE genotype was found to moderate the effects of multimorbidity clusters on the risk of dementia.

Conclusions Early identification of older adults at higher risk of accumulating multimorbidity of specific pathophysiology and tailored interventions to prevent or delay the onset of such multimorbidity may help prevention of dementia.

  • DEMENTIA
  • CLUSTER ANALYSIS
  • COHORT STUDIES
  • EPIDEMIOLOGY

Data availability statement

Data may be obtained from a third party and are not publicly available. UK Biobank data access agreement does not allow to share data publicly. However, data are accessible directly from the UK Biobank via appropriate project applications.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Data availability statement

Data may be obtained from a third party and are not publicly available. UK Biobank data access agreement does not allow to share data publicly. However, data are accessible directly from the UK Biobank via appropriate project applications.

View Full Text

Footnotes

  • Twitter @MizanKhondoker, @N/A

  • Contributors MK conceived the idea, MK and LS designed the study with contributions from AM, MOB, MH and CF. AM guided on the inflammation aspects of the project. AM, MH and CF advised on selection of chronic conditions. MOB advised on pathophysiology-based grouping of multimorbidity. MH advised on the selection of dementia ICD 10 codes. MK analysed the data, written-up and revised the manuscript. All authors provided critical feedback on important intellectual contents, edited the manuscript and contributed to the interpretation of data and discussion of results. The corresponding author (MK) is responsible for the overall content.

  • Funding This study was funded by Norwich Medical School, University of East Anglia.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • © Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.

  • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.